Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report.

Clinical lung cancer - 1 Sept 2021

Zhang Yaping, Wang Hui, Wang Xiaoyan, Li Shuai, Fang Hongming

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Aged, 80 and over
Share to Anaplastic Lymphoma Kinase
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Treatment Outcome

Source

Identifiers

PMID: 33640300
DOI: 10.1016/j.cllc.2021.01.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report.PMID 33640300Read ↗

Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Precision treatment for metastatic non-small cell lung cancer: A conceptual overview.Semantic proximity Read ↗

Gene aberrations for precision medicine against lung adenocarcinoma.Semantic proximity Read ↗

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Semantic proximity Read ↗

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.Semantic proximity Read ↗

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?Semantic proximity Read ↗

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenarioSemantic proximity Read ↗

Top advances of the year: Precision oncology.Semantic proximity Read ↗

Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.Semantic proximity Read ↗

Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.Semantic proximity Read ↗

Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.Semantic proximity Read ↗

Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.